Autism Spectrum Program of Excellence | Clinical Research Studies Listing

Recruiting

3 years - 99 years

All

Phase N/A

500 participants needed

1 Location

Brief description of study

The goal of the ASPE study is to investigate the genetic basis of autism spectrum disorder (ASD) and autism-related traits.

Individuals 3 years old or older with a diagnosis (or suspected diagnosis) of autism spectrum disorder without intellectual disability may be eligible to participate.

We are also recruiting individuals with a deletion in the NRXN1 gene (2p16.3 deletion) and their family members.

Additionally, we are recruiting people who are not on the autism spectrum to act as our control (comparison) group.

Visit www.aspe.med.upenn.edu or contact a member of the study team at aspe@pennmedicine.upenn.edu to learn how you can join the ASPE Study's growing community today!

Detailed description of study

Participation includes:

- Completing a series of online questionnaires

- Returning a free saliva kit for DNA analysis

- Option to wear a research grade (FitBit-like) device to track activity and sleep

- All completed in the comfort of your own home!

Eligible individuals who enroll and complete all questionnaires will be compensated $50 for participating.

You do not need to be located in the Philadelphia area to participate. All participation can be completed from the comfort of your home.

For Additional Information

Visit our website:

https://aspe.med.upenn.edu

Or contact a member of the study team at aspe@pennmedicine.upenn.edu to learn more!

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Autism,Aspergers,ASD,AS,NRXN1,Autism spectrum disorder,2p16.3 deletion
Age: 3 years - 99 years
Gender: All

Individuals with an autism diagnosis or suspected autism diagnosis
Individuals with a Chromosome 2p16.3 deletion / NRXN1 gene deletion and their family members
People who are not on the autism spectrum (no diagnosis and no suspected diagnosis)

Updated on 15 Oct 2024. Study ID: 826701

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).